Metabolic & body composition
MOTS-c
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending.
A mitochondrial-derived peptide studied for insulin sensitivity, metabolic flexibility and exercise capacity.
What it is
MOTS-c is encoded in mitochondrial DNA rather than nuclear DNA — one of a small group of peptides that appear to act as signals from the mitochondria to the rest of the cell. Research focuses on AMPK activation, glucose handling and exercise adaptation.
What it's studied for
- Insulin sensitivity and glucose uptake in animal models
- Exercise capacity and metabolic flexibility
- Age-related decline in circulating levels
How it's used in practice
- Discussed in short research cycles rather than continuously
- Effects in the literature overlap heavily with what training itself produces
What you should know before asking about it
- Research use only; not FDA-approved
- Human clinical data is minimal
- Prohibited in competitive sport
Frequently asked questions.
- What is MOTS-c?
- MOTS-c is encoded in mitochondrial DNA rather than nuclear DNA — one of a small group of peptides that appear to act as signals from the mitochondria to the rest of the cell. Research focuses on AMPK activation, glucose handling and exercise adaptation.
- What is MOTS-c studied for?
- Published and ongoing research looks at insulin sensitivity and glucose uptake in animal models; exercise capacity and metabolic flexibility; age-related decline in circulating levels. These are areas of study, not promised outcomes.
- Is MOTS-c FDA-approved?
- MOTS-c has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.
- How is MOTS-c typically used?
- Discussed in short research cycles rather than continuously Effects in the literature overlap heavily with what training itself produces Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with MOTS-c?
- Research use only; not FDA-approved Human clinical data is minimal Prohibited in competitive sport
Sources
- 1.Published literature on MOTS-c— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Metabolic & body composition
Single Regulator (GLP-1) — semaglutide
Semaglutide, listed as Single Regulator (GLP-1) because compounded formulations cannot be marketed under the drug's commercial name. A GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.
Dual Regulator (GLP-1/GIP) — tirzepatide
Tirzepatide, listed as Dual Regulator (GLP-1/GIP) because compounded formulations cannot be marketed under the drug's commercial name. A GIP/GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.
Triple Regulator (GLP-1/GIP/glucagon)
An investigational triple agonist (GLP-1, GIP and glucagon) in late-stage clinical trials — not approved, not prescribable.